Natures Sunshine Products Inc. NATR
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Natures Sunshine Products Inc. (NATR) is a healthcare company listed in the US with a market value of about $180M. In the twelve months to September 30, 2026 it had revenue of $480M and net income of $15M, a net margin of 3.1%.
Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is track record (0/5).
Key numbers: a P/E of 12.6, a price to free cash flow of 17.1, 5-year revenue growth of 4% a year, a 5-year average ROIC of 11%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 8% above the current price.
About Natures Sunshine Products
Natures Sunshine Products is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $366M in 2014 to $480M in 2025, growth of about 2.5% a year. It was profitable in 7 of the last 10 years in our data. Its share count fell by 4% over three years (buybacks). It spends 0% of revenue on research and development.
Score: 2.4 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- Profit margin improving
- More cash than debt, or low debt to equity
- Positive free cash flow
- Interest covered more than 5 times
Checks not passed
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $480M | $480M | $454M | $445M | $422M | $444M | $385M | $362M | $365M | $342M | $341M |
| Net income | $15M | $20M | $8M | $15M | -$390000 | $29M | $21M | $7M | -$854000 | -$13M | $2M |
| Free cash flow | $11M | $29M | $14M | $31M | -$7M | $28M | $33M | $3M | $17M | $5M | -$8M |
| EPS (diluted) | $0.82 | $1.06 | $0.40 | $0.77 | $-0.02 | $1.42 | $1.07 | $0.34 | $-0.04 | $-0.69 | $0.11 |
| Net margin | 3.1% | 4.1% | 1.7% | 3.4% | -0.1% | 6.5% | 5.5% | 1.9% | -0.2% | -3.8% | 0.6% |
| ROIC | — | 9.4% | 9.1% | 8.7% | 7.7% | 17.9% | 9.3% | 8.2% | 2.9% | 0.8% | 5.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Natures Sunshine Products’s P/E ratio?
About 12.6, based on the last twelve months of diluted earnings per share.
Is Natures Sunshine Products stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 8% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Natures Sunshine Products pay a dividend?
Not currently.
Is Natures Sunshine Products a good stock to buy?
We do not give buy or sell advice. Natures Sunshine Products scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.